VEGFA and hepatocellular carcinoma: In the current research on inhibitors of the VEGF pathway, sorafenib, cabozantinib, and sunitinib have all been studied in clinical trials in HCC, but their monotherapy effect is less than satisfactory (ORR, 4%, 4%, and 2.7%) (12–14).